Elevated Lp(a) levels are not yet driving more aggressive lipid lowering therapy, according to an analysis of Lp(a) testing in patients in a university-based health system since 2013.
Educational Partners and Supporters
AstraZeneca has provided a sponsorship grant towards this independent programme.
